The Cause - How you can make a difference

“You have cancer.” The three words you never want to hear. Imagine finding that out. Imagine living with it. Imagine knowing that there was a better way to treat your cancer but it was going to be at least four years before anything can be done about it.

Now, imagine knowing a way to bring that treatment to you or your loved one sooner. Imagine clinical trials that that produce new treatments and better ways of caring for those with cancer.

That can be a reality and by supporting ANZUP, you can make it happen.

Use of Funds

Funds are needed to conduct clinical trials. Typically, it takes between two and three years from the initial idea for ANZUP to know whether we will receive funding. This is before any trial can take place. That’s a long time between coming up with a potentially life-changing solution and implementing it as a new practice.

If ANZUP raises enough money to be self-funding, trials could begin within a much shorter time frame. This means evidence and change outcomes for our patients can happen in a lot less time than it currently takes.

The Below the Belt Research Fund is the first step in allowing ANZUP's researchers to conduct the intial phases of trial research. Through your contribution three researchers were granted $50,000 each in 2016 to answer critical questions in prostate, bladder and testicular cancer research.

The Below the Belt Research Fund - How you have made a real difference

We know that we need a pipeline of new ideas in order to keep trial momentum moving forward. Ideas do not mean much unless we can translate them into clinical trials. The more we can do this then the more opportunities we will have to improve outcomes for our patients. 

It can be challenging to obtain the initial funding to move a concept through to being a viable clinical trial. That’s why the ANZUP Below the Belt Research Fund has been established: to move new ideas into the next evolutionary step and to help improve the prospect of full funding support and completion.  Thanks to your support through the Below the Belt Pedalthon we are closer to defeating these cancers.

2017 Successful Applications

Camille Short - Delivering personalised and evidence-based exercise support to men with metastatic prostate cancer via the internet - A pilot RCT examining intervention impact on behaviour change and quality of life.

Megan Crumbaker & Anthony Joshua - Bipolar androgen therapy (BAT) in men with metastatic castrate-refractory prostate cancer

Lisa Horvath - Statins in Metastatic Castration-Resistant Prostate Cancer (CRPC)

Haryana Dhillon - Patient perception of adherence to treatment advice in urogenital and prostate cancers: a qualitative exploration.

Dickon Hayne - ANZUP co-operative multi-centre cystectomy database (ACCEPT)      

Dennis Taafe - Exercise Medicine Prior to Open Radical Cystectomy: Feasibility and Preliminary Efficacy

2016 Successful Applications

Allan Ben Smith - e-TC 2.0: Further development of an online psychological intervention for testicular cancer survivors

I am Dr Allan ‘Ben’ Smith, Translational Research Fellow, Centre for Oncology Education and Research Translation (CONCERT), Ingham Institute of Applied Medical Research

Why am I doing this? Using the Internet to extend the reach and accessibility of psychosocial care for people affected by cancer, particularly for male cancer survivors who may be reluctant to seek more traditional forms of help, such as face-to-face therapy.

Internet-based interventions appear particularly well suited to helping survivors of testicular cancer, the most common cancer in men aged 20-39, who suffer from poorer quality of life and greater anxiety and depression. 

My research will hopefully improve outcomes for testicular cancer survivors by using Internet-delivered interventions to overcome barriers to accessing care, including stigma, inconvenience and cost. I have developed an online psychological intervention for testicular cancer survivors (e-TC) together with a multidisciplinary team from the Psycho-Oncology Co-operative Research Group (PoCoG) and Australian and New Zealand Urogential and Prostate Cancer Trials Group (ANZUP). 

I really appreciate the support of the Below the Belt Research Fund, which is essential to determining whether e-TC is a feasible way to deliver information and support to testicular cancer survivors suffering from anxiety and/or depression. 

Carmel Pezaro  - Defining primary resistance to chemohormonal treatment with docetaxel in men with metastatic hormone-sensitive prostate cancer: a preliminary biomarker cohort study.

I am a Medical Oncologist at Monash University in Melbourne, focused on clinical and translational research into prostate cancer. I am particularly interested to study why some men with advanced prostate cancer respond less well to the standard initial hormonal and chemotherapy treatments. This will help my research team and I to identify a group of men who should receive more intensive treatment, or who should be studied separately to find more effective therapies. I am very grateful for the support of the Below the Belt Research Fund, enabling us to undertake this work.

Andrew Weickhardt - Circulating immune cell changes in patients treated with pembrolizumab and chemoradiation for bladder cancer.

I work in Melbourne at Olivia Newton-John Cancer and Research Institute as an oncologist and translational scientist. My area of research is in using drugs that stimulate the immune system to improve cure rates for patients with bladder cancer. My research is comparing changes in the levels of immune cells in patients having new immunotherapies with chemotherapy and radiation to those patients who receive chemoradiation alone. We hope to improve outcomes of patients by better understanding how these new immune therapies work and which patients should receive them. Thanks for your support. 

Our Challenge

To make a difference by raising awareness and attracting charitable donations to improve treatments and outcomes.

We need to answer the question for our patients "how can we do this better?"

Our Targets

$50k-$250k – Kick off a pilot study

Will allow us to invest in a pilot study to test the feasibility of promising drug therapies, surgical methods, post-operative care and palliative care options.  We were able to conduct 4 of these concept development meetings as a result of the 2014 Pedalthon. This means eight or more new treatments are being worked on right now.

$1m-$5m – Support a clinical trial

Will allow us to invest in a clinical trial to test the effectiveness, side effects and best dose of potential treatments for urogenital cancers.

This year, let’s do better. Let your imagination become an inspiration as we continue improving treatments and outcomes for those affected by these cancers. 

Morton logo GenesisCare logoPfizer OncologyThirdi Group logo
powered by Everyday Hero